Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that the US Food and Drug Administration (FDA) has granted Priority Review to the nipocalimab Biologics License Application (BLA) for the treatment of antibody-positive generalised myasthenia gravis (gMG).
This decision is supported by positive results from the Phase 3 Vivacity-MG3 study, which demonstrated significant improvement in disease control with nipocalimab plus standard of care compared with placebo plus standard of care.
gMG is a rare autoimmune disease affecting approximately 700,000 people globally. Priority Review typically results in a shorter FDA review period, aiming to expedite the availability of potentially life-changing therapies.
J&J has also submitted a Marketing Authorisation Application for nipocalimab in gMG to the European Medicines Agency and received Breakthrough Therapy Designation from the FDA for the treatment of Sjögren's disease.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024